Table 1 Baseline characteristics of the cohort overall and by ART delivery site
Overall | By ART delivery site | ||||||
|---|---|---|---|---|---|---|---|
Site A | Site B | Site C | Site D | Site E | |||
n | 953 | 165 | 238 | 198 | 145 | 207 | |
Age (years) | Median | 41 | 38 | 39 | 44 | 39 | 44 |
IQR | 35–46 | 34–41 | 34–44 | 39–48 | 32–46 | 37–49 | |
Sex | Male (%) | 95.9 | 97.0 | 97.1 | 99.0 | 91.0 | 94.2 |
CD4 (× 106/l) | Median | 156 | 177 | 140 | 160 | 131 | 169 |
(IQR) | 86–230 | 106–280 | 77–205 | 83–250 | 88–185 | 101–222 | |
WHO stage* | 1–2 (%) | 27.0 | 16.0 | 12.8 | 28.4 | 38.8 | 45.7 |
3 | 46.2 | 36.4 | 47.7 | 53.6 | 45.5 | 45.7 | |
4 | 26.8 | 47.5 | 39.6 | 18.0 | 15.7 | 8.7 | |
Viral load (copies/ml) | <= 10,000 (%) | 20.1 | 20.1 | 20.5 | 18.1 | 16.7 | 24.0 |
10,001–100,000 | 49.7 | 46.5 | 50.5 | 51.3 | 48.6 | 50.5 | |
>100,000 | 30.3 | 33.3 | 29.0 | 30.6 | 34.8 | 25.5 | |
Weight (kg) | Median | 63 | 64 | 65 | 61 | 60 | 65 |
IQR | 57–69 | 59–69 | 59–70 | 56–68 | 52–67 | 60–73 | |
ART regimen | COM/EFV (%) | 94.1 | 96.4 | 94.5 | 97.0 | 86.9 | 94.2 |